Krahasoni metodat

	Provë Klinike Faza I Bayesiane	Provë e Përshtatshme e Randomizuar Klinike
Fusha	Epidemiologji	Epidemiologji
Familja	Process / pipeline	Process / pipeline
Viti i origjinës	1990	Late 1990s–2000s (widespread adoption post-2010)
Krijuesi	O'Quigley, Pepe & Fisher (Continual Reassessment Method)	Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019
Lloji	Adaptive Bayesian dose-finding design	Experimental clinical trial design
Burimi themelues	O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48.	Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36.
Emërtime të tjera	Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study	adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial
Të lidhura	5	6
Përmbledhja	A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.	An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study.